These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 34210720)

  • 1. Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol.
    Gu B; De Gregorio M; Pipicella JL; Vande Casteele N; Andrews JM; Begun J; Connell W; D'Souza B; Gholamrezaei A; Hart A; Liew D; Radford-Smith G; Rimola J; Sutherland T; Toong C; Woods R; Wu Y; Xuan W; Williams AJ; Ng W; Ding NS; Connor S
    BMJ Open; 2021 Jul; 11(7):e043921. PubMed ID: 34210720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn's disease.
    Gu B; Venkatesh K; Williams AJ; Ng W; Corte C; Gholamrezaei A; Ghaly S; Xuan W; Paramsothy S; Connor S
    World J Gastroenterol; 2022 Jun; 28(23):2597-2608. PubMed ID: 35949350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial).
    Papamichael K; Jairath V; Zou G; Cohen B; Ritter T; Sands B; Siegel C; Valentine J; Smith M; Vande Casteele N; Dubinsky M; Cheifetz A
    BMJ Open; 2022 Apr; 12(4):e057656. PubMed ID: 35365535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease.
    Davidov Y; Ungar B; Bar-Yoseph H; Carter D; Haj-Natour O; Yavzori M; Chowers Y; Eliakim R; Ben-Horin S; Kopylov U
    J Crohns Colitis; 2017 May; 11(5):549-555. PubMed ID: 28453755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Infliximab on Deep Radiological Remission in Chinese Patients with Perianal Fistulizing Crohn's Disease.
    Zhu M; Xu X; Feng Q; Cui Z; Wang T; Yan Y; Ran Z
    Dig Dis Sci; 2021 May; 66(5):1658-1668. PubMed ID: 32524415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab serum concentrations and disease activity in perianal fistulizing Crohn's disease: a cross-sectional study.
    Miranda EF; Nones RB; Baraúna FB; de Nardi Marçal G; Olandoski M; de Moraes TP; Kotze PG
    Tech Coloproctol; 2024 Jul; 28(1):86. PubMed ID: 39031218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy.
    Papamichael K; Cheifetz AS
    World J Gastroenterol; 2017 Sep; 23(34):6197-6200. PubMed ID: 28974885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn's disease: a retrospective cohort study.
    Zhu P; Sun JF; Gu YF; Chen HJ; Xu MM; Li YR; Yang BL
    BMC Gastroenterol; 2022 Jan; 22(1):15. PubMed ID: 35012467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease.
    Yarur AJ; Kanagala V; Stein DJ; Czul F; Quintero MA; Agrawal D; Patel A; Best K; Fox C; Idstein K; Abreu MT
    Aliment Pharmacol Ther; 2017 Apr; 45(7):933-940. PubMed ID: 28211593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of endoscopic ultrasound to guide combination medical and surgical therapy for patients with Crohn's perianal fistulas.
    Schwartz DA; White CM; Wise PE; Herline AJ
    Inflamm Bowel Dis; 2005 Aug; 11(8):727-32. PubMed ID: 16043987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas.
    De Gregorio M; Lee T; Krishnaprasad K; Amos G; An YK; Bastian-Jordan M; Begun J; Borok N; Brown DJM; Cheung W; Connor SJ; Gerstenmaier J; Gilbert LE; Gilmore R; Gu B; Kutaiba N; Lee A; Mahy G; Srinivasan A; Thin L; Thompson AJ; Welman CJ; Yong EXZ; De Cruz P; van Langenberg D; Sparrow MP; Ding NS
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1306-1314. PubMed ID: 34389484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab maintenance therapy for fistulizing Crohn's disease.
    Sands BE; Anderson FH; Bernstein CN; Chey WY; Feagan BG; Fedorak RN; Kamm MA; Korzenik JR; Lashner BA; Onken JE; Rachmilewitz D; Rutgeerts P; Wild G; Wolf DC; Marsters PA; Travers SB; Blank MA; van Deventer SJ
    N Engl J Med; 2004 Feb; 350(9):876-85. PubMed ID: 14985485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients.
    Strik AS; Löwenberg M; Buskens CJ; B Gecse K; I Ponsioen C; Bemelman WA; D'Haens GR
    Scand J Gastroenterol; 2019 Apr; 54(4):453-458. PubMed ID: 31032686
    [No Abstract]   [Full Text] [Related]  

  • 15. Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn's disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA.
    Minar PP; Colman RJ; Zhang N; Mizuno T; Vinks AA
    BMJ Open; 2024 Mar; 14(3):e077193. PubMed ID: 38531570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
    Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local injection of infliximab in severe fistulating perianal Crohn's disease: an open uncontrolled study.
    Alessandroni L; Kohn A; Cosintino R; Marrollo M; Papi C; Monterubbianesi R; Tersigni R
    Tech Coloproctol; 2011 Dec; 15(4):407-12. PubMed ID: 22011835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study.
    Srinivasan A; van Langenberg D; De Cruz P; Segal J; Vasudevan A; Upton RN
    BioDrugs; 2024 Sep; 38(5):691-702. PubMed ID: 39168947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction and Maintenance Infliximab Therapy for the Treatment of Crohn's Disease with Perianal Fistulas in Children: Retrospective, Multicenter Study.
    Iwańczak BM; Ryżko J; Jankowski P; Sładek M; Wasilewska A; Szczepanik M; Sienkiewicz E; Szaflarska-Popławska A; Więcek S; Kwiecień J; Korczowski B; Maślana J
    Adv Clin Exp Med; 2016; 25(3):523-30. PubMed ID: 27629741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn's disease.
    Plevris N; Jenkinson PW; Arnott ID; Jones GR; Lees CW
    Eur J Gastroenterol Hepatol; 2020 Jan; 32(1):32-37. PubMed ID: 31567638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.